Cardiology

Top Story

ROCKET AF: High number of medications affects bleeding risk, not stroke risk

ROCKET AF: High number of medications affects bleeding risk, not stroke risk
February 8, 2016

In patients with nonvalvular atrial fibrillation from the ROCKET AF trial, higher number of medications was associated with increased risk for bleeding, but not increased risk for stroke, researchers found.

Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS, and colleagues compared adjusted outcomes between those assigned rivaroxaban (Xarelto, Janssen Pharmaceuticals) and those assigned warfarin in ROCKET AF by number of medications at baseline, as well as the presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors, which are currently contraindicated for use with rivaroxaban.

Trial ScorecardsPublication Exclusive

Trial Scorecard: RESCUE

Cardiology Today, February 2016
Comparison of survivability and efficacy in patients with severe ischemic HF after CABG alone or CABG plus cardiac resynchronization therapy.
Trial ScorecardsPublication Exclusive

Trial Scorecard: SITAGRAMI

Cardiology Today, February 2016
Researchers compared the effects of sitagliptin in combination with granulocyte-colony stimulating factor (Lenograstim) in patients undergoing PCI for acute MI.
Trial ScorecardsPublication Exclusive

Trial Scorecard: LIPS2

Cardiology Today, February 2016
Researchers compared rates of death or new MI in patients with popliteal and infrapopliteal peripheral artery disease who underwent balloon angioplasty with laser…
Trial ScorecardsPublication Exclusive

Trial Scorecard: ExcelsiorLOAD

Cardiology Today, February 2016
Researchers investigated the extent to which preloading with prasugrel inhibited platelet activity vs. clopidogrel in patients with stable CAD undergoing PCI.
More News Headlines »
morganatic-roan